PAST BURKITT MEDAL AWARDEES

Burkitt Medal Awardee 2022 – Prof. Eileen O'Reilly

Dr. Eileen M. O’Reilly holds the Winthrop Rockefeller Endowed Chair in Medical Oncology at Memorial Sloan Kettering (MSK). She serves as the Section Head for Hepatopancreaticobiliary/ Neuroendocrine Cancers, Gastrointestinal Oncology Service, Co-Director for Medical Initiatives at the David M. Rubenstein Center for Pancreatic Cancer and is an Attending Physician and Member at MSK and Professor of Medicine at Weill Cornell Medical College.

Dr. O’Reilly received her medical degree at Trinity College (Dublin University) in Ireland. She completed her residency training in Ireland and Fellowship training at MSK. Dr. O’Reilly has pancreatic and hepatobiliary malignancies as the major focus of her research and clinical activities. She is a clinical scientist whose research focus involves integration of molecular and genetic-based therapies for pancreas cancer along with development of adjuvant and neoadjuvant therapies and identification of biomarkers for therapy selection. Dr. O’Reilly teaches and mentors junior faculty, oncology fellows, residents and medical/other students and has numerous teaching and other awards. Dr. O’Reilly is the Principal Investigator of multiple phase I, II, III trials in pancreas cancer and has authored/co-authored > 330 articles, editorials, and book chapters. She serves as an Associate Editor for the Journal of Clinical Oncology and Senior Editor for several other journals and has served on multiple grant review panels including, for the American Society of Clinical Oncology (ASCO), American Association of Cancer Research (AACR), NIH and various international entities.

Dr. O’Reilly’s other responsibilities include: Chair of the Institutional Review & Privacy Board (IRB) and Chair of the Continuing Medical Education (CME) committee at MSK. Nationally Dr. O’Reilly is Co-Chair of the NCI Alliance Co-Operative Group Gastrointestinal Cancers Committee and serves on the NCI Gastrointestinal Cancers Steering Committee (GISC), Medical and Scientific Advisory Board of Pancreatic Cancer Action Network, ASCO Guidelines Committee and the Board of the National Pancreas Foundation.

Burkitt Medal Awardee 2019 – Mina Bissell, PhD

MINA J. BISSELL is Distinguished Scientist, the highest rank bestowed at Lawrence Berkeley National Laboratory (LBNL) and serves as Senior Advisor to the Laboratory Director on Biology. She is also Faculty of four Graduate Groups in UC Berkeley: Comparative Biochemistry, Endocrinology, Molecular Toxicology, and Bioengineering (UCSF/UCB joint). Having challenged several established paradigms, Bissell is a pioneer in breast cancer research and her body of work has provided much impetus for the current recognition of the significant role that extracellular matrix (ECM) signalling and microenvironment play in gene expression regulation in both normal and malignant cells. Her laboratory developed novel 3D assays and techniques that demonstrate her signature phrase: aft er conception, “phenotype is dominant over genotype.” Bissell earned her doctorate from Harvard Medical, won an American Cancer Society fellowship, and soon aft er joined LBNL. She was founding Director of the Cell and Molecular Biology Division and later Associate Laboratory Director for all Life Sciences. Bissell has published more than 400 publications, received numerous honours and awards and is one of the most sought-aft er speakers in the field. She is not only an elected Fellow of most U.S. honorary scientific academies, but she also sits on many national and international scientific board

Burkitt Medal Awardee 2017 – Mariano Barbacid, PhD

Mariano Barbacid is AXA-CNIO Professor of Molecular Oncology at the Spanish National Cancer Research Centre in Madrid. Born in Madrid, Mariano Barbacid was awarded his PhD from the Universidad Complutense in 1974. Having trained as a postdoctoral fellow at the National Cancer Institute (NCI), Bethesda, Maryland, USA, in 1978 he started his own group to work on the molecular biology of human tumours. Dr Barbacid’s work led to the isolation of the first human cancer gene, H-RAS, in the spring of 1982 and to the identification of the first mutation associated with the development of human cancer. These findings, also made independently by two other groups, have been seminal to establish the molecular basis of human cancer. Dr Barbacid’s achievements have been recognised widely. In 2012, he was inducted to the National Academy of Sciences of the US as a Foreign Member and in 2014, elected Fellow of the AACR Academy. He holds three Honorary degrees, and apart from being acknowledged for his achievements in Spain, Dr Barbacid received several international awards including the Steiner Prize (Bern, 1988), Ipsen Prize (Paris, 1994), Brupbaher Cancer Research Prize (Zurich, 2005), the Medal of Honour of the International Agency for Cancer Research (Lyon, 2007) and an Endowed Chair from the AXA Research Fund (Paris, 2011). He has received two Advanced Grants from the European Research Council since their inception in 2008. To date, Dr Barbacid has authored a total of 300 publications, including 221 original research articles in journals with impact factor, 32 invited reviews in refereed journals and 47 book chapters.

Burkitt Medal Awardee 2016 – Paul Brennan, PhD

Paul Brennan is the Head of the Genetics Section of the International Agency for Research on Cancer (IARC), Lyon, France. IARC is the specialised cancer agency of the World Health Organization (WHO) with the objective to promote international collaboration in cancer research. Dr Brennan's primary area of work is conducting very large multi-partner studies that aim to use genetics to understand the causes of cancer. This is done by exploring the genome of individuals who develop cancer, in order to identify clues as to why they are more susceptible. It also involves investigating the genomes of the tumours, in order to identify what triggered the tumour in the first place. His group works with colleagues in many different parts of the world, with active studies underway in central and eastern Europe, central and south-east Asia, and Latin America. Among others, Dr Brennan has collaborators in Trinity College Dublin. Dr Brennan and his colleagues at IARC have made an outstanding contribution to promoting international collaboration in the study of cancer for the ultimate benefit of those affected by the disease.

Burkitt Medal Awardee 2015 – Riccardo Dalla-Favera, MD, MSc

Riccardo Dalla-Favera is Professor of Pathology & Cell Biology and Director, Institute for Cancer Genetics at Columbia University, New York, USA. Professor Dalla-Favera’s career started with his pioneering work on the cloning and chromosomal mapping of human proto-oncogenes, including c-MYC. This work established the basis for the seminal work on the involvement of c-MYC in chromosomal translocations in Burkitt’s lymphoma. His research has continued to yield new insights into the pathogenesis of human B cell lymphomas, and, in particular, on the identification of the genetic lesions and biological mechanisms responsible for the development of these diseases.

Burkitt Medal Awardee 2014 – John L. Ziegler, MD, MSc

John Ziegler, Founding Director, Global Health Sciences Graduate Program University of California San Francisco (UCSF), USA, received his undergraduate degree (BA, English Literature) from Amherst College, Amherst Massachusetts, and his MD from Cornell University Medical School in New York City. Following medical house staff training at Bellevue Hospital in New York, he joined the National Cancer Institute (NCI) in 1966, beginning a life-long career in cancer research and care. In 1967 he was assigned to begin a long collaboration with Makerere University in Kampala, Uganda, studying Burkitt’s lymphoma and other indigenous cancers. Together with Ugandan counterparts, he developed curative therapies for lymphoma and established a cancer institute that today has expanded to a major center of excellence in sub Saharan Africa. After five years Ziegler returned to NCI to head clinical oncology, and in 1981 moved to UCSF. The AIDS pandemic made its first appearance in San Francisco, heralded by opportunistic infections and two malignancies – Kaposi’s sarcoma and non Hodgkin’s lymphoma. Ziegler and colleagues made important contributions to this field both in California and back in Uganda. In his later career, earning an MSc in epidemiology from the London School of Hygiene and Tropical Medicine, Ziegler headed a cancer genetics clinic at UCSF, and most recently was founding director of a global health Master’s degree.

Burkitt Medal Awardee 2013 – Murray F. Brennan, MD

Born in Auckland, New Zealand, Dr. Murray Brennan received a degree in mathematics from the University of New Zealand and a medical degree from the University of Otago in 1964. In 1970 he worked at Peter Bent Brigham Hospital, Harvard Medical School, and at the Joslin Research Laboratories. After residency at the Brigham, Dr. Brennan joined the National Cancer Institute. In 1981, he joined Memorial Sloan-Kettering Cancer Center (MSKCC) as Chief of Gastric and Mixed Tumor Service. Dr. Brennan was Chairman of the Department of Surgery at MSKCC from 1985 until June of 2006. He currently holds the Benno C. Schmidt Chair in Clinical Oncology and is Director of the International Center and Vice President for International Programs at MSKCC. He has lectured throughout the world and authored and co-authored more than 1,000 scientific papers and book chapters focusing on surgical oncology, endocrinology, metabolism, and nutrition, and is the author of a book on soft tissue sarcoma. Dr Brennan received numerous honours for his contribution to oncology. Dr. Brennan’s interest, in addition to patient care and research, has been the development of young surgeons.